Palladium One Mining Inc. (TSXV: PDM) (OTCQB: NKORF) (FSE: 7N11) (the “Company” or “Palladium One”) is pleased to report that a high-resolution airborne magnetic survey has commenced at Tyko and that the Company has acquired an additional 4,520 hectares through staking contiguous with the Tyko Nickel – Copper Project, in Ontario, Canada (Figure 1).
Figure 1. New Tyko property position map showing various mineralized zones, multi-line VTEM anomalies and interpreted feeder dyke / chonolith structures. Background is the 2021 survey magnetic survey Calculated Vertical Gradient (“CVG”). Greyed out zones are controlled by third parties.
President and CEO, Derrick Weyrauch commented, “This low-cost strategic expansion of the Tyko property secures additional ground interpreted to host prospective feeder dykes / chonolith structures. The 2023 high-resolution magnetic survey, that is currently being flown, will incorporate these new claims and will greatly refine structures across the entire property. Results of the magnetic survey will be compiled in 3D along with a broad soil sampling / mapping program that is scheduled to start in Q2.”
The new high-resolution magnetic survey is being flown by helicopter at 75-meter spacings and will comprise 4,520 line-kilometres. The survey is expected to be completed in February. The increased resolution of this survey will enable the Company to “see through the clutter” of the numerous later cross cutting diabase dykes at Tyko and improve drill targeting of the feeder dykes / chonolith structures.
Figure 1. New Tyko property position map showing various mineralized zones, multi-line VTEM anomalies and interpreted feeder dyke / chonolith structures. Background is the 2021 survey magnetic survey Calculated Vertical Gradient (“CVG”). Greyed out zones are controlled by third parties. https://images.newsfilecorp.com/files/6502/152488_845f83cc7452ab84_001full.jpg.
About Tyko Nickel – Copper – Cobalt Project
The Tyko Nickel – Copper – Cobalt Project, is located approximately 65 kilometers northeast of Marathon Ontario, Canada. Tyko is an early stage, high sulphide tenor, nickel – copper (2:1 ratio) project and currently has five known mineralized zones spanning over a 20 kilometer strike length.
Qualified Person
The technical information in this release has been reviewed and verified by Neil Pettigrew, M.Sc., P. Geo., Vice President of Exploration and a director of the Company and the Qualified Person as defined by National Instrument 43-101.
About Palladium One
Palladium One Mining Inc. (TSXV: PDM) is focused on discovering environmentally and socially conscious Metals for Green Transportation. A Canadian mineral exploration and development company, Palladium One is targeting district scale, platinum-group-element (PGE)-copper-nickel deposits in Canada and Finland. The Lantinen Koillismaa (LK) Project in north-central Finland, is a PGE-copper-nickel project that has existing NI43-101 Mineral Resources, while both the Tyko and Canalask high-grade nickel-copper projects are located in Ontario and the Yukon, Canada, respectively. Follow Palladium One on LinkedIn, Twitter, and at www.palladiumoneinc.com.
ON BEHALF OF THE BOARD “Derrick Weyrauch” President & CEO, Director
For further information contact: Derrick Weyrauch, President & CEO Email: info@palladiumoneinc.com
Eisai Co., Ltd. today announced that it has initiated preparation on a New Drug Application for ultrahigh-dose mecobalamin (development code: E0302) for amyotrophic lateral sclerosis (ALS) in Japan, based on a favorable clinical results of the JETALS (The Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for ALS: JETALS), an investigator-initiated Phase III trial to evaluate efficacy and safety of ultrahigh-dose methylcobalamin (mecobalamin) in early onset ALS patients, published by a research team led by Extraordinary Professor Ryuji Kaji (Principal Investigator), Tokushima University and Professor Yuishin Izumi (Coordinating Investigator), the Department of Neurology, Tokushima University Graduate School of Biomedical Sciences. Eisai submitted an application for an orphan drug designation of this agent to the Ministry of Health, Labour and Welfare (MHLW) in March 2022, and plans to submit a new drug application in fiscal year 2023.
For ultrahigh-dose mecobalamin, Eisai submitted a new drug application as treatment for ALS in May 2015 based on the results of a Phase II/III clinical trial (Study 761) for ALS, but withdrew the application in March 2016 after receiving the opinion about the application package not being sufficient from the Pharmaceuticals and Medical Devices Agency (PMDA).
However, an additional analysis of Study 761 suggested that ultrahigh-dose mecobalamin prolonged survival period and suppressed progression in ALS patients who commenced treatment within 12 months of ALS onset. In order to re-examine its efficacy and safety in ALS patients within 1 year of onset, JETALS was conducted as an investigator-initiated clinical trial by the research team led by the Tokushima University with the support of the Japan Agency for Medical Research and Development (AMED). The results of the study showed the efficacy, safety, and tolerability of ultrahigh-dose mecobalamin, which have now been published in the peer-reviewed journal JAMA Neurology(New Window). Based on the results of JETALS, in consultation with the Tokushima University, Eisai has decided to newly submit the application for approval of ultrahigh-dose mecobalamin for ALS in Japan.
Eisai considers neurology a therapeutic area of focus and is committed to new drug development in this field in order to fulfill unmet medical needs and further contribute to increasing the benefit for patients and their families.
About Amyotrophic Lateral Sclerosis (ALS)
ALS is an intractable, progressive, neurodegenerative disease that results in severe muscle atrophy and weakness in the muscles due to motor neuron dysfunction. As the main cause of death is respiratory failure due to paralysis of the respiratory muscles, without the use of an artificial respirator, death occurs within approximately 3 to 6 years from the onset of the disease. According to the number of patients issued a Certificate of the Recipient of Specified Disease Treatment, there were 10,514 patients with ALS in Japan in 2020. Currently, there is no curative treatment established for ALS, and since there are only limited number of medicines approved in Japan and abroad, this is a disease with significant unmet medical needs.
About Mecobalamin
Mecobalamin (development code: E0302) is approved and marketed as Methycobal, a 500 microgram injection of mecobalamin indicated for the treatment of peripheral neuropathies and megaloblastic anemia caused by vitamin B12 deficiency. Methycobal is also approved as a tablet formulation as well as a fine granule formulation indicated for the treatment of peripheral neuropathies. While the mechanism of action of mecobalamin in ALS is not known, it has been suggested in non-clinical research that mecobalamin may have efficacy through a neuroprotective effect and regeneration of nerve axons. Since the 1990s, clinical research has been carried out on ultrahigh-dose mecobalamin in ALS by a study group on neurodegenerative disease, funded through the Ministry of Health, Labour and Welfare’s Specified Disease Treatment Research Program. Short- and long-term trials of intramuscular injection of mecobalamin at 25 mg and 50 mg per day, which is respectively 50 and 100 times the approved dosage of Methycobal, suggested that ultrahigh-dose mecobalamin could have a clinical effect in ALS.Therefore, Eisai had conducted the Phase II/III clinical trial (Study 761) since 2006 and submitted a new drug application for ultrahigh-dose mecobalamin as treatment for ALS in May 2015 but withdrew the application in March 2016 after the Pharmaceuticals and Medical Devices Agency (PMDA) indicated that additional clinical trials were necessary.
Media Inquiries: Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120
The Canadian International Trade Tribunal today initiated a preliminary injury inquiry into a complaint by Restwell Mattress Co. Ltd., of Surrey, British Columbia, and the United Steelworkers, of Toronto, Ontario, that they have suffered injury as a result of the dumping and subsidizing of mattresses from the People’s Republic of China. The Tribunal’s inquiry is conducted pursuant to the Special Import Measures Act (SIMA) as a result of the initiation of dumping and subsidizing investigations by the Canada Border Services Agency (CBSA).
Ottawa, Ontario, February 25, 2022—The Canadian International Trade Tribunal today initiated a preliminary injury inquiry into a complaint by Restwell Mattress Co. Ltd., of Surrey, British Columbia, and the United Steelworkers, of Toronto, Ontario, that they have suffered injury as a result of the dumping and subsidizing of mattresses from the People’s Republic of China. The Tribunal’s inquiry is conducted pursuant to the Special Import Measures Act (SIMA) as a result of the initiation of dumping and subsidizing investigations by the Canada Border Services Agency (CBSA).
On April 25, 2022, the Tribunal will determine whether there is a reasonable indication that the alleged dumping and subsidizing have caused injury or retardation, or are threatening to cause injury, as these words are defined in SIMA. If so, the CBSA will continue its investigations and, by May 25, 2022, will make preliminary determinations. If these preliminary determinations indicate that there has been dumping or subsidizing, the CBSA will then continue its investigations and, concurrently, the Tribunal will initiate a final injury inquiry.
The Tribunal is an independent quasi-judicial body that reports to Parliament through the Minister of Finance. It hears cases on dumped and subsidized imports, safeguard complaints, complaints about federal government procurement and appeals of customs and excise tax rulings. When requested by the federal government, the Tribunal also provides advice on other economic, trade and tariff matters.
Any interested person, association or government that wishes to participate in the Tribunal’s inquiry may do so by filing a Form I – Notice of Participation. For more information, visit the Tribunal’s website.
Today, Vesalio announced the start of enrollment in its NATURE study using enVast™, the company’s first thrombectomy system for patients presenting with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention.
NATURE is a randomized, multi-center clinical trial comparing the safety and efficacy of enVast™ as an adjunctive measure to conventional intervention versus the standard of care in STEMI patients with large thrombus burden.
The first patient in the study was enrolled by Professor Marco Valgimigli, Deputy Chief of Cardiology at Cardiocentro Ticino Istituto, in Lugano, Switzerland.
“Our first-in-human case series of 61 STEMI patients with large thrombus burden allowed us to develop a safe and effective thrombectomy technique using the enVast™ stent retriever under continuous aspiration. With the NATURE study, our goal is to assess the comparative effectiveness of this novel technique versus the standard of care. The results could provide a new therapeutic opportunity for patients with large thrombus burden, who still represent a major challenge for procedural success and long-term outcomes,” said Dr. Valgimigli.
Coronary Artery Disease is the number one cause of death globally. Approximately 17 million patients experience myocardial infarction every year, with more than 3 million presenting with a large thrombus burden in STEMI. “We are excited to diversify the use of our Drop Zone™ technology and venture into this critical indication, where we anticipate making a positive impact on patient outcomes as Vesalio has achieved in stroke intervention,” commented Steve Rybka, Vesalio Chief Executive Officer.
The Vesalio enVast™ coronary thrombectomy system is CE approved.
About Vesalio Founded in 2013, Vesalio is a privately held medical device company committed to advancing patient care in vascular occlusion by providing physicians superior technology designed to improve clinical outcomes. The company’s proprietary NeVa™ platform was designed to consistently achieve first-pass recanalization in acute ischemic stroke by effectively removing all types of neurovascular clots from patient anatomy.
For more information, please visit vesalio.com, email info@vesalio.com, or connect with us on LinkedIn or Twitter.
Vesalio William von Brendel 858-335-5790 www.vesalio.com
The Canadian International Trade Tribunal today initiated an inquiry to determine whether the dumping of oil country tubular goods originating in or exported from the Republic of Austria has caused injury or retardation or is threatening to cause injury. This final injury inquiry was initiated further to a notice received from the Canada Border Services Agency stating that a preliminary determination had been made respecting the dumping of the above-mentioned goods.
Ottawa, Ontario, October 26, 2021—The Canadian International Trade Tribunal today initiated an inquiry to determine whether the dumping of oil country tubular goods originating in or exported from the Republic of Austria has caused injury or retardation or is threatening to cause injury. This final injury inquiry was initiated further to a notice received from the Canada Border Services Agency stating that a preliminary determination had been made respecting the dumping of the above-mentioned goods.
On February 22, 2022, the Tribunal will determine whether the dumping has caused injury or retardation or is threatening to cause injury to the domestic industry.
The Tribunal is an independent quasi-judicial body that reports to Parliament through the Minister of Finance. It hears cases on dumped and subsidized imports, safeguard complaints, complaints about federal government procurement and appeals of customs and excise tax rulings. When requested by the federal government, the Tribunal also provides advice on other economic, trade and tariff matters.
Any interested person, association or government that wishes to participate in the Tribunal’s inquiry may do so by filing Form I – Notice of Participation. For details on the specific product under inquiry or for more information, visit the Tribunal’s website.
Contact